Bioasis Technologies Inc. 107.F Stock
Bioasis Technologies Inc. Price Chart
Bioasis Technologies Inc. 107.F Financial and Trading Overview
| Bioasis Technologies Inc. stock price | 0.0080 EUR |
| Previous Close | 0.0045 EUR |
| Open | 0.0045 EUR |
| Bid | 0.0045 EUR x 0 |
| Ask | 0.02 EUR x 0 |
| Day's Range | 0.0045 - 0.0045 EUR |
| 52 Week Range | 0.0005 - 0.19 EUR |
| Volume | 2.4K EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 1.11M EUR |
| Beta (5Y Monthly) | 0.353054 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.03 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.61 EUR |
107.F Valuation Measures
| Enterprise Value | 2.37M EUR |
| Trailing P/E | N/A |
| Forward P/E | -0.089999996 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.1121035 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 8.816 |
| Enterprise Value/EBITDA | -0.797 |
Trading Information
Bioasis Technologies Inc. Stock Price History
| Beta (5Y Monthly) | 0.353054 |
| 52-Week Change | -97.080% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.19 EUR |
| 52 Week Low | 0.0005 EUR |
| 50-Day Moving Average | 0.0035 EUR |
| 200-Day Moving Average | 0.05 EUR |
107.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 79.41M |
| Float | 77.96M |
| Short Ratio | N/A |
| % Held by Insiders | 2.05% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | February 28, 2022 |
| Most Recent Quarter (mrq) | November 30, 2022 |
| Next Fiscal Year End | February 28, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1141.15% |
| Gross Margin | -259.66% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -80.58% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 269.38K EUR |
| Revenue Per Share (ttm) | 0.004 EUR |
| Quarterly Revenue Growth (yoy) | 294.80% |
| Gross Profit (ttm) | -1188430 EUR |
| EBITDA | -2980693 EUR |
| Net Income Avi to Common (ttm) | -2875838 EUR |
| Diluted EPS (ttm) | -0.03 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 156.52K EUR |
| Total Cash Per Share (mrq) | 0.002 EUR |
| Total Debt (mrq) | 2.21M EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.106 |
| Book Value Per Share (mrq) | -0.034 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -1936522 EUR |
| Levered Free Cash Flow (ttm) | -310482 EUR |
Profile of Bioasis Technologies Inc.
| Country | Germany |
| State | CT |
| City | New Haven |
| Address | 157 Church Street |
| ZIP | 06510 |
| Phone | 203 533 7082 |
| Website | https://www.bioasis.us |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.
Q&A For Bioasis Technologies Inc. Stock
What is a current 107.F stock price?
Bioasis Technologies Inc. 107.F stock price today per share is 0.0080 EUR.
How to purchase Bioasis Technologies Inc. stock?
You can buy 107.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Bioasis Technologies Inc.?
The stock symbol or ticker of Bioasis Technologies Inc. is 107.F.
Which industry does the Bioasis Technologies Inc. company belong to?
The Bioasis Technologies Inc. industry is Biotechnology.
How many shares does Bioasis Technologies Inc. have in circulation?
The max supply of Bioasis Technologies Inc. shares is 79.41M.
What is Bioasis Technologies Inc. Price to Earnings Ratio (PE Ratio)?
Bioasis Technologies Inc. PE Ratio is now.
What was Bioasis Technologies Inc. earnings per share over the trailing 12 months (TTM)?
Bioasis Technologies Inc. EPS is -0.03 EUR over the trailing 12 months.
Which sector does the Bioasis Technologies Inc. company belong to?
The Bioasis Technologies Inc. sector is Healthcare.